Spencer founded Spira in Seattle in 2007 and has since helped create two dozen new high tech companies, including Agios Pharmaceuticals [NASDAQ:AGIO], Receptos [NASDAQ:RCPT] , Fate Therapeutics [NASDAQ:FATE] , Syros Pharmaceuticals [NASDAQ:SYRS] and Sapphire Energy. He has also negotiated $350MM in strategic relationships for biotechnology companies and non-profit institutions. Prior to founding Spira, Spencer was vice president of tech transfer at the Fred Hutchinson Cancer Research Center working for Nobel Laureate, Leland Hartwell. Spencer previously directed similar efforts at Wake Forest University School of Medicine and NC State University. Spencer has assisted in the creation of dozens of new companies including Ikaria, BlackThorn Therapeutics, Agios Pharmaceuticals [NASDAQ:AGIO], Sapphire Energy, Receptos [NASDAQ:RCPT], Fate Therapeutics [NASDAQ:FATE], Point DX. (acquired by IDXC;now GE Healthcare), and Biolex. Spencer has served as vice president of the Association of University Technology Managers (AUTM) and on the AUTM Board. He has also been a guest speaker at numerous national meetings for AUTM, the Association of American Medical Colleges (AAMC), the Association of Independent Research Institutes (AIRI), the Licensing Executives Society (LES), and the American Chemical Society (ACS).